Pulmonary Toxicity in Stage III Non-Small Cell Lung Cancer Patients Treated With High-Dose (74 Gy) 3-Dimensional Conformal Thoracic Radiotherapy and Concurrent Chemotherapy Following Induction Chemotherapy: A Secondary Analysis of Cancer and Leukemia Group B (CALGB) Trial 30105

CALGB 30105 tested two different concurrent chemoradiotherapy platforms with high dose (74 Gy) 3-D conformal radiotherapy (3DCRT) following two cycles of induction chemotherapy for stage IIIA/IIIB NSCLC patients to determine if either could achieve a primary endpoint of > 18 month median survival. Final results of 30105 demonstrated that induction carboplatin and gemcitabine and concurrent gemcitabine 3DCRT was not feasible due to treatment related toxicity. However, induction and concurrent carboplatin/paclitaxel with 74 Gy 3DCRT had a median survival of 24 months, and is the basis for the experimental arm in CALGB 30610/RTOG 0617/N0628. We conducted a secondary analysis of all patients to determine predictors of treatment related pulmonary toxicity